About Us


48-49 Russell Square, London, WC1B 4JP UK

T: +44 (0)203 0084416

E: info@valirx.com


ValiPharma is a biopharmaceutical company focused on developing personalised medicines to bring more advanced therapeutic options for the treatment of cancer. For many years the Company has progressively exploited its proprietary epigenomic technology, which has led to the discovery of promising therapeutics that may prove in clinical trials to combat cancer safely and more effectively than currently used chemotherapeutics, which act indiscriminately, attacking the whole body and causing irreparable damage to normal cellular processes.

Currently, ValiPharma has two lead drug candidates in late stage pre-clinical development for three indications – VAL 101 for androgen independent prostate cancer, and VAL 201 for hormone refractory prostate cancer, and endometriosis.

scientific testing